MOPH (Lebanon)

Lebanon MoPH (Ministry of Public Health — Lebanese Republic) — operating through the Pharmaceutical Directorate + the Quality Assurance of Pharmaceutical Products Department (QAPP) + the Central Laboratory for Drug Control + the Pharmacy Inspection Department — is the Lebanese Republic's national regulatory authority for human medicines + biologicals + vaccines + medical devices + IVDs + cosmetics + dietary supplements + pharmacy practice + controlled substances. Lebanon MoPH operates under Law 367 of 1994 (Pharmacy Practice + Pharmaceutical Establishments) + Decree 571 of 1983 (Drug Registration) + Law 530 of 1996 (Pharmaceutical Industry) + Law 673 of 1998 (Narcotics + Psychotropics) + Ministerial Decisions + Pharmaceutical Directorate Circulars + Guidance Documents.

Lebanon MoPH organisational structure includes:

• Minister of Public Health — political head appointed by the Council of Ministers.
• Director General of the Ministry of Public Health.
• Pharmaceutical Directorate — the principal medicines regulator coordinating Drug Registration + Pricing + Inspection + Pharmacovigilance.
• Drug Registration Department — drug + biological + vaccine + biosimilar + generic-medicine registration under Decree 571/1983.
• Pricing Department — distinctive substantial role given Lebanese government price-control framework + currency-crisis-driven pricing complexity.
• Pharmacy Inspection Department — GMP + GDP + GPP + GVP + GLP inspections of Lebanese + foreign manufacturing facilities.
• Quality Assurance of Pharmaceutical Products Department (QAPP) — pharmaceutical quality assurance + product evaluation + post-market quality surveillance.
• Central Laboratory for Drug Control — central pharmaceutical QC laboratory; pursuing ISO/IEC 17025 expansion + WHO PQ-Lab designation.
• Lebanese National Pharmacovigilance Programme — WHO PIDM-affiliated PV centre.
• Medical Devices coordination — medical-device + IVD registration + matériovigilance.
• Cosmetics + Dietary Supplements coordination — cosmetic-product + dietary-supplement notification.
• Controlled Substances coordination with Internal Security Forces + INCB + Lebanese Customs.
• International Affairs Section — WHO + EMA + ANSM + FDA + Arab League + EMRO coordination.

Lebanon MoPH is distinct from + complementary to: the Order of Pharmacists of Lebanon (OPL — professional licensing body for individual pharmacists), the Syndicate of Pharmaceutical Industries in Lebanon (SPIL — domestic manufacturer trade association), the Syndicate of Pharmaceutical Importers (industry trade association), the Lebanese University Faculty of Pharmacy + Université Saint-Joseph Faculty of Pharmacy + Lebanese American University School of Pharmacy + Beirut Arab University Faculty of Pharmacy (pharmacy education), and UN-agency + NGO healthcare operators including UNHCR + UNRWA + UNICEF + WHO + MSF + ICRC + Lebanese Red Cross supporting substantial refugee + vulnerable-population pharmaceutical access. Lebanon's pharmaceutical environment is uniquely characterised by: longstanding regional pharmaceutical-manufacturing tradition with ~25+ domestic manufacturers historically serving Lebanon + GCC + MENA export markets; substantial currency-crisis + economic-crisis-driven access-to-medicines challenges since October 2019 including substantial subsidised-medicines framework adjustments + import-finance disruptions; mixed public/private healthcare delivery with substantial private sector + substantial NGO + UN-agency-supported humanitarian healthcare for ~1.5 million Syrian refugees + ~470,000 Palestinian refugees; trilingual Arabic + English + French labelling environment reflecting Francophone medical-pharmacy tradition + Anglophone medical education; and Mediterranean Climate Zone II pharmaceutical-stability environment with coastal humidity in Beirut + Tripoli + Sidon + Tyre offset by drier Bekaa + Mount Lebanon conditions.

Lebanon MoPH is an active League of Arab States Council of Arab Ministers of Health pharmaceutical-harmonisation co-leader + a WHO Eastern Mediterranean Regional Office (EMRO) participant + an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority + a WHO PIDM member + maintains substantial historical regulatory alignment with French ANSM + EMA + Health Canada + FDA reflecting Lebanon's Francophone medical-pharmacy tradition + Mandate-era institutional inheritance + diaspora-driven North-American clinical-pharmacy training links.

Lebanese pharmaceutical regulation operates under a layered framework of Laws + Decrees + Ministerial Decisions + Pharmaceutical Directorate Circulars + Guidance Documents:

• Law 367 of 1994 — Pharmacy Practice + Pharmaceutical Establishments framework.
• Decree 571 of 1983 — Drug Registration framework + subsequent amending Decrees.
• Law 530 of 1996 — Pharmaceutical Industry framework establishing the basis for Lebanese domestic manufacturing licensure.
• Law 673 of 1998 — Narcotics + Psychotropics framework substantively aligned with UN Single Convention 1961 + Conventions 1971 + 1988.
• Ministerial Decisions + Pharmaceutical Directorate Circulars on Medical Devices + Cosmetics + Dietary Supplements.
• MoPH GMP Guide — substantively aligned with PIC/S GMP Guide + EU GMP + ICH Q7 + WHO TRS 986 Annex 2; historical French ANSM alignment particularly influential.
• MoPH GDP Guide — substantively aligned with WHO + EU GDP.
• MoPH GCP Guide — substantively aligned with ICH E6(R2) — given Lebanon's substantial clinical-research capacity via AUB + USJ + LAU + LU academic medical centres.
• MoPH GVP Guide — substantively aligned with ICH E2 + EU GVP.
• Pharmacopoeia recognition — recognises European Pharmacopoeia + British Pharmacopoeia + USP + French Pharmacopoeia + Arab Pharmacopoeia.
• Subsidised Medicines List + Essential Medicines List — distinctive substantial framework given currency-crisis-driven subsidy adjustments since 2019.
• MoPH Medical Devices framework — Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF.
• MoPH Cosmetics framework — substantively aligned with EU Cosmetics Regulation including INCI ingredient listing + safety substantiation.
• MoPH Variations + 5-year Drug Registration Renewal framework.
• MoPH Pricing framework — distinctive substantial role given Lebanese government price-control framework + Reference Country pricing + currency-crisis-driven pricing complexity.

The Central Laboratory for Drug Control is MoPH's principal pharmaceutical quality-control laboratory + is pursuing ISO/IEC 17025 scope expansion + WHO PQ-Lab designation. The Quality Assurance of Pharmaceutical Products Department (QAPP) coordinates pharmaceutical quality assurance + product evaluation + post-market quality surveillance. Lebanon's QC infrastructure has historically benefited from substantial French ANSM + EMA + WHO technical cooperation + has supported the longstanding ~25+ manufacturer Lebanese pharmaceutical-manufacturing industry serving Lebanon + GCC + MENA + African export markets.

• ISO/IEC 17025 — Central Laboratory for Drug Control pursuing ISO/IEC 17025 scope expansion across pharmaceutical chemical + microbiological + biological testing.
• WHO PQ-Lab Candidate — Lebanon Central Laboratory pursuing WHO PQ-Lab designation; would position alongside Saudi SFDA Central Laboratory + Egypt EDA NODCAR + Morocco LNCM + Tunisia LNCM + Jordan JFDA Central Laboratories as WHO-prequalified pharmaceutical QC laboratories in the MENA region.
• Vaccine lot release — the Laboratory conducts vaccine lot-release testing for MoPH + the Lebanese Expanded Programme on Immunization including UNICEF + WHO + Gavi-supported procurement.
• Pharmaceutical pre-registration + post-market testing — pre-registration quality testing + post-market surveillance + targeted enforcement testing including substantial counterfeit-medicine forensic capacity given Lebanon's geographic position at MENA crossroads.
• Medical-device + IVD testing — pre-market + post-market quality testing.
• Cosmetic-product + dietary-supplement testing — safety + ingredient compliance testing.
• Counterfeit-medicine forensics — forensic analytical support for MoPH + Internal Security Forces + Lebanese Customs investigations + WHO Global Surveillance & Monitoring System contributions.
• Capacity-building — historically hosts French ANSM + EMA + WHO + Arab League capacity-building programmes + training for MENA pharmaceutical analysts.
• GMP Inspectorate support — provides scientific + technical support for MoPH Pharmacy Inspection Department GMP inspections of Lebanese + foreign manufacturing facilities.
• QAPP coordination — pharmaceutical quality assurance + product evaluation + post-market quality surveillance + Variations + Renewal coordination.
• Refugee-population medicine quality — distinctive substantial role given large refugee populations + UN-agency + NGO humanitarian-procured medicines requiring post-market quality verification.

MoPH medical-device + IVD regulation operates under MoPH Medical Devices framework with Class I-III risk-based classification substantively aligned with EU MDR + GHTF/IMDRF. Foreign manufacturers must appoint a Lebanese Authorised Representative. Lebanon's medical-device market is served by both Lebanese-domestic + foreign manufacturers + substantial UN-agency + NGO humanitarian-imported devices for refugee + vulnerable-population healthcare.

• Risk-based Classification (Class I / IIa / IIb / III) — substantively aligned with EU MDR + GHTF/IMDRF; IVDs classified under separate framework.
• Lebanese Authorised Representative — Lebanon-resident legal entity required for foreign manufacturers; bears post-market vigilance responsibility + MoPH regulatory interface.
• ISO 13485:2016 — recognised by MoPH as QMS evidence framework; Lebanon-specific overlay required.
• Reliance pathways — MoPH accepts CE Mark + FDA 510(k) + FDA PMA + Health Canada + TGA + Swissmedic + ANSM evidence as supporting evidence; CE Mark + ANSM particularly central reflecting Lebanon's Francophone EU alignment.
• Arab League Medical Devices Harmonisation — Lebanon participates in Council of Arab Ministers of Health medical-device harmonisation.
• Post-market vigilance — MoPH operates medical-device adverse-event reporting; reporting timelines substantively aligned with IMDRF Adverse Event Reporting Codes.
• IVD Réactovigilance — MoPH operates IVD réactovigilance reflecting Lebanon's substantial clinical-laboratory infrastructure including AUB Medical Center + Hôtel-Dieu de France + Rafik Hariri University Hospital + Saint George Hospital University Medical Center networks.
• Cosmetic Notification — cosmetics require MoPH Cosmetic Notification + Arabic + English + French trilingual labelling; INCI-aligned ingredient listing + safety substantiation; substantively EU-aligned framework.
• Dietary Supplement Registration — MoPH Dietary Supplements framework; substantively aligned with EU food-supplement framework + Codex Alimentarius.
• Humanitarian Device Importation — substantial UN-agency + NGO humanitarian medical-device + IVD importation framework for refugee + vulnerable-population healthcare programmes; coordinated with WHO + UNHCR + UNICEF + UNRWA.
• Importation Permit — MoPH Importation Permit required in addition to product registration for foreign-manufactured devices + drugs entering Lebanon; coordination with Lebanese Customs + Ministry of Economy and Trade.

MoPH operates the Lebanese National Pharmacovigilance Programme. Lebanon is a WHO Programme for International Drug Monitoring (PIDM) member + contributes ADR data to VigiBase via Uppsala Monitoring Centre (UMC). The Lebanese National PV Programme coordinates with university medical centres + private hospitals + UN-agency + NGO humanitarian-healthcare operators. Lebanon's pharmacovigilance is uniquely shaped by substantial refugee population vaccine + essential-medicines safety surveillance commitments + currency-crisis-driven supply-chain quality risk monitoring.

• Lebanese National Pharmacovigilance Programme — coordinated by MoPH Pharmaceutical Directorate.
• WHO PIDM Member — Lebanon is a WHO PIDM member + contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Lebanese PV Network — coordinated national network with effector centres in major Lebanese hospitals (AUB Medical Center, Hôtel-Dieu de France, Rafik Hariri University Hospital, Saint George Hospital University Medical Center, Lebanese American University Medical Center-Rizk Hospital, Bellevue Medical Center, Clemenceau Medical Center, Mount Lebanon Hospital, Sahel General Hospital) + Marketing Authorisation Holders.
• ADR Reporting — MoPH operates ADR reporting via MoPH portal; available for healthcare professionals + consumers + Marketing Authorisation Holders.
• E2B(R3) ICSR — MoPH accepts E2B(R3) format ICSR submissions substantively aligned with ICH E2B(R3); 15-day SUSAR reporting timeline for clinical trials + post-market.
• PSUR / PBRER — periodic safety update reports substantively aligned with ICH E2C(R2); MoPH-specific submission timeline.
• Risk Management Plans (RMP) — MoPH requires ICH E2E-aligned Pharmacovigilance Plan + Risk Management Plan for new drugs + biosimilars + vaccines + high-risk products.
• Active surveillance — Lebanese National PV Programme operates targeted active-surveillance programmes for COVID-19 vaccines + childhood immunisation + oncology + biologicals.
• Refugee + vulnerable-population PV — distinctive substantial commitments for Syrian refugee + Palestinian refugee + Lebanese-vulnerable-population vaccine + essential-medicines safety surveillance coordinated with UNHCR + UNRWA + UNICEF + WHO.
• AEFI Surveillance — Lebanese vaccine adverse-event surveillance aligned with WHO methodology; central to Lebanese Expanded Programme on Immunization + UNICEF + Gavi + WHO-supported immunisation campaigns.
• Matériovigilance + Cosmétovigilance — MoPH operates parallel matériovigilance for medical devices + cosmétovigilance for cosmetics.
• Currency-crisis quality-risk monitoring — distinctive substantial role given currency-crisis-driven supply-chain disruption + counterfeit-medicine + substandard-medicine surveillance.
• Arab League Pharmacovigilance — Lebanon participates in Arab League Council of Arab Ministers of Health pharmacovigilance harmonisation.

• WHO EMRO Participant — Lebanon MoPH is an active WHO Eastern Mediterranean Regional Office (EMRO) participant; substantial WHO + UN-agency humanitarian healthcare cooperation.
• WHO PQ CRP Participating Authority — MoPH is an active WHO Prequalification Collaborative Registration Procedure (CRP) participating authority.
• WHO PQ-Lab Candidate — Lebanon Central Laboratory for Drug Control pursuing WHO PQ-Lab designation.
• WHO PIDM Member — Lebanon contributes ADR data to VigiBase via Uppsala Monitoring Centre.
• Arab League Council of Arab Ministers of Health Co-leader — MoPH is an active pharmaceutical-harmonisation co-leader alongside Egyptian EDA + Saudi SFDA + Jordanian JFDA + UAE MoHAP + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP + Kuwait MoH + Bahrain NHRA + Oman MoH + Qatar MoPH.
• French ANSM Bilateral — MoPH maintains substantial historical bilateral cooperation with ANSM reflecting Lebanon's Francophone medical-pharmacy tradition + Mandate-era institutional inheritance + Université Saint-Joseph + Lebanese University Faculty of Pharmacy Francophone medical-education ties.
• EMA Cooperation — MoPH maintains substantial EU reliance practice + cooperation including French + German + Italian + Spanish + EMA centralised + decentralised + mutual-recognition + national authorisation reliance.
• Health Canada Bilateral — MoPH maintains substantial Health Canada reliance reflecting Lebanese diaspora-driven Canadian clinical-pharmacy training links.
• FDA Bilateral — MoPH maintains substantial FDA cooperation reflecting American University of Beirut + Lebanese American University US-medical-education ties + Lebanese diaspora-driven US clinical-pharmacy training links.
• TGA + Swissmedic + MHRA + MFDS Bilateral — MoPH maintains Stringent Regulatory Authority reliance practice.
• PIC/S Cooperation — MoPH GMP Guide substantively aligned with PIC/S GMP + EU GMP + ICH Q7; PIC/S Pre-Accession dialogue.
• ICH Observer Practice — ICH guidelines extensively implemented in Lebanese regulatory practice including ICH Q7 + Q8 + Q9 + Q10 + Q11 + E2A-E + M4.
• ICDRA + EMRO participation — active International Conference of Drug Regulatory Authorities + WHO EMRO participant.
• UN-Agency Humanitarian Cooperation — substantial cooperation with UNHCR + UNRWA + UNICEF + UNFPA + UNDP + WHO + ICRC + MSF + Lebanese Red Cross for refugee + vulnerable-population healthcare programmes; among most substantial UN-agency humanitarian pharmaceutical operational frameworks globally.

• Lebanese Authorised Representative not properly designated — application rejected at MoPH intake or post-approval compliance failure; Lebanese Authorised Representative must be Lebanon-resident legal entity with appropriate licensure.
• Arabic + English + French trilingual labelling deficiencies — Arabic required + English + French commonly required; many applicants provide insufficient French-language patient leaflet despite Lebanon's Francophone medical-pharmacy tradition.
• MoPH GMP gaps — applicants assuming EU GMP / PIC/S GMP / FDA GMP compliance is automatically sufficient without addressing Lebanon-specific MoPH GMP clarifications.
• Lebanon climate-zone stability data missing — Lebanon is Climate Zone II (Beirut + coastal) + Climate Zone I (mountain) requiring zonal-specific stability data.
• Bioequivalence centres + biowaiver — MoPH BE Guidance provides BCS-based biowaivers; applicants frequently submit BE studies where biowaivers would suffice.
• WHO PQ CRP reliance under-utilised — WHO-PQ-approved products eligible for accelerated MoPH CRP review (90-day target); under-utilised by many applicants.
• EMA + ANSM + SRA reliance under-utilised — MoPH operates substantial reliance on EMA + ANSM + Stringent Regulatory Authority decisions; ANSM reliance particularly under-utilised by non-Francophone applicants despite Lebanon's Francophone regulatory tradition.
• Arab League harmonisation not leveraged — Council of Arab Ministers of Health pharmaceutical-harmonisation reliance under-utilised.
• Subsidised Medicines List strategy missing — distinctive substantial framework given currency-crisis-driven subsidy adjustments since 2019; inclusion strategy frequently overlooked by foreign manufacturers.
• UN-Agency humanitarian procurement pathway not leveraged — substantial WHO + UNHCR + UNICEF + UNRWA + UNFPA humanitarian procurement opportunity for refugee + vulnerable-population healthcare programmes frequently overlooked.
• Essential Medicines + Vital Medicines accelerated pathway not leveraged — accelerated Registration under-utilised; 90-120 calendar day target.
• Currency-crisis-driven pricing complexity not planned — distinctive substantial pricing framework adjustments since 2019 require specific pricing-strategy planning frequently overlooked.
• Counterfeit-medicine + substandard-medicine quality risks under-monitored — Lebanon's geographic MENA crossroads position + currency-crisis-driven supply-chain disruption create substantial counterfeit + substandard medicine quality risks requiring substantial post-market quality surveillance frequently overlooked.
• Variations strategy not planned — variations procedure substantively similar to EU but with Lebanon-specific timelines + fee structure + currency-crisis-driven administrative delays.
• Registration renewal timing missed — 5-year renewal must be filed within prescribed window before expiry; missed deadline triggers de-registration.
• Clinical trial ethics coordination steps — Lebanon clinical trials require MoPH CTA + relevant Institutional Review Board (AUB IRB / USJ IRB / LAU IRB / LU IRB / private-hospital IRB) approval; Lebanon's substantial academic-medical-centre clinical-research capacity provides substantial opportunity frequently overlooked by sponsors.

V5 Ultimate provides the operational infrastructure Lebanese + foreign-supplier sites need for Law 367 of 1994 + Decree 571 of 1983 + Law 530 of 1996 + MoPH GMP + Medical Devices framework + WHO PQ CRP + EMA + ANSM bilateral + Arab League + Lebanese National Pharmacovigilance Programme + UN-agency humanitarian procurement + Subsidised Medicines List + currency-crisis-driven pricing-strategy readiness.

• MoPH GMP control framework — PIC/S + EU GMP + ICH Q7 + ANSM-aligned controls with ALCOA+ data-integrity + Lebanon-specific clarifications + Climate Zone I + II stability monitoring.
• MoPH Registration dossier packaging — Lebanon CTD-aligned dossier structure with Lebanon Module 1 specifics + Module 3 stability + Arabic + English + French trilingual patient leaflet + Authorised Representative declarations + Law 367 of 1994 + Decree 571 of 1983 + Law 530 of 1996 framework.
• WHO PQ CRP workflow — MoPH-as-CRP-participating-authority packaging with reduced dossier + accelerated MoPH review (90-day target).
• EMA + ANSM reliance workflow — MoPH-EMA + MoPH-ANSM cooperation packaging for EMA + French-approved products; particularly substantial for Francophone-tradition products.
• Health Canada + FDA + TGA + Swissmedic + MHRA + MFDS reliance workflow — Stringent Regulatory Authority reliance packaging.
• Arab League workflow — Council of Arab Ministers of Health pharmaceutical-harmonisation packaging.
• Subsidised Medicines List + Essential Medicines workflow — distinctive substantial framework given currency-crisis-driven subsidy adjustments since 2019 + Essential Medicines + Vital Medicines accelerated Registration packaging.
• UN-Agency humanitarian procurement workflow — WHO + UNHCR + UNICEF + UNRWA + UNFPA + UNDP humanitarian procurement framework packaging for refugee + vulnerable-population healthcare programmes.
• Lebanese Authorised Representative workflow — foreign-manufacturer Authorised Representative designation + role-management + Lebanon-specific post-market surveillance.
• Lebanese clinical-trial workflow — MoPH CTA + AUB IRB / USJ IRB / LAU IRB / LU IRB / private-hospital IRB coordination + Lebanese SUSAR reporting via Lebanese National PV Programme; leverages Lebanon's substantial academic-medical-centre clinical-research capacity.
• Lebanese National PV Programme integration — E2B(R3) ICSR generation + 15-day SUSAR timeline + PSUR / PBRER packaging + Arabic + English + French ICSR + Lebanese PV Network coordination + VigiBase upload + Risk Management Plan packaging + AEFI vaccine adverse-event reporting + refugee + vulnerable-population safety surveillance.
• Matériovigilance + Cosmétovigilance workflow — parallel matériovigilance + cosmétovigilance packaging.
• Medical-device + IVD + cosmetic + dietary-supplement workflow — MoPH frameworks dossier packaging + Class I-III classification + ISO 13485 + Authorised Representative + post-market vigilance.
• Currency-crisis-driven pricing-strategy workflow — distinctive substantial pricing framework adjustments since 2019 + Subsidised Medicines List + Reference Country pricing strategy packaging.
• Counterfeit + substandard medicine surveillance workflow — Lebanon's geographic MENA crossroads position + currency-crisis-driven supply-chain disruption monitoring + WHO Global Surveillance & Monitoring System integration.
• Arab League + Mashreq + Francophone Maghreb regional bridging — for companies operating across Arab League + Francophone-tradition jurisdictions, V5 surfaces MoPH + Jordan JFDA + Egyptian EDA + Saudi SFDA + UAE MoHAP + Morocco DMP + Tunisia DPM/ANPM + Algeria ANPP harmonised dossier-element reuse alongside national-specific extensions.